Grit Biotechnology

Grit Biotechnology is a Chinese biotechnology company founded in 2019, with the slogan "Developing novel cell therapies to transform the lives of people with cancer." The company focuses on developing tumor-infiltrating lymphocyte (TIL) therapy programs to address unmet medical needs for patients with solid tumors. Their product GT101, the first non-gene-modified TIL product to receive Investigational New Drug (IND) approval in China, is currently in Phase 1 clinical trials. Grit Bio has established three core technology platforms for TIL development: StaViral®, a retroviral system tailored for TIL engineering, ImmuT Finder®, a high-throughput screening platform identifying novel T-cell targets, and StemTexp®, a TIL expansion platform that enriches TCM and TSCM populations of TIL. The company is leveraging these platforms to develop a potentially best-in-class gene-engineered TIL therapy. In its latest funding round, Grit Biotechnology raised CNY400.00M in a Series B investment on 08 September 2023. The investors in this round included Matrix Partners China, Decheng Capital, CICC, Yuanhe Capital, HeFangTian Venture Partnership, Qianhai Ark, Liando Group, and Sherpa Healthcare Partners. This investment signifies the confidence of prominent venture capital firms in Grit Bio's vision and potential in the biotechnology and healthcare industries.